1349.HK

FUDANZHANGJIANG | Cotação de Ações

Última atualização20/05/2025, 05:08:38

PreçoHK$ 2,65

Variação (dia)HK$ 0,04 (1.53%)▲

Min. 52 SemanasHK$ 1,70

Máx. 52 SemanasHK$ 4,42

Capitalização de mercado--

Endereço: Zhangjiang Hi-Tech Park, Shanghai, 201210

Telefone: 86 21 5895 3355

Funcionários: 921

FUDANZHANGJIANG1349.HK

HK$ 2,65

+ 0,041,5%

20/05/2025 05:08:38

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualHK$ 2,65

Valor de mercado--

AberturaHK$ 2,59

Preço máximoHK$ 2,70

Preço mínimoHK$ 2,59

VolumeHK$ 4,4 mi

Fechamento anteriorHK$ 2,61

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and HER2 ADC that is in phase I clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which have complected Phase IV clinical trial; and Aminolevulinic acid CIN, which have complected phase II clinical trials for cervical diseases infected by HPV; Aminolevulinic acid AK, which is in phase II clinical trials for Actinic keratosis; Aminolevulinic acid acne, which is in phase II clinical trials for Acne; Aminolevulinic acid gliomas for Surgical visualization of gliomas; Aminolevulinic acid bladder for Surgical visualization of bladder cancer; and Aminolevulinic acid breast that has obtained phase I clinical trial approval for Surgical visualization of breast cancer. In addition, it offers Osmotic pump technology platform drugs, which includes Controlled-release carbidopa/levodopa Tablets which have complected phase II clinical trials for Early Parkinson's disease; and Obeticholic acid for the treatment of Hepatobiliary diseases/ Autoimmune diseases. Further, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

Ações relacionadas

DYNAGREEN ENV

1330.HK ▲0.01% | HK$ 3,34

LIFETECH SCI

1302.HK ▼0.01% | HK$ 1,30

SH PIONEER HLDG

1345.HK ▼0.00% | HK$ 2,30

SHANGHAI FUDAN

1385.HK ▼0.70% | HK$ 14,50

CC SECURITIES

1375.HK ▼0.07% | HK$ 1,57

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Explore os ativos do mercado financeiro em tempo real com a nossa API

A API da brapi proporciona uma visão dos ativos do mercado financeiro. Com gráficos interativos e dados atualizados, oferecemos uma análise abrangente das tendências do mercado. Os desenvolvedores podem personalizar os módulos, configurar o range de tempo e escolher todos os dados necessários para decisões informadas.

Acesse a Documentação para uma compreensão detalhada da nossa plataforma

Explore a Documentação para uma compreensão detalhada de como utilizar efetivamente nossa plataforma para análise de investimentos. Oferecemos recursos abrangentes para orientar investidores, desde iniciantes até experientes, na navegação por nossa plataforma.